Full Press Release Details
Conference attendance follows recent MOU announcement for a joint venture with a regional manufacturing and distribution company in the Kingdom of Saudi Arabia
SALT LAKE CITY, Oct. 22, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that members of the Company's executive leadership team will be in attendance and host a booth at Global Health Exhibition 2025 at the Riyadh Exhibition & Convention Center on October 27-30 in Riyadh, Kingdom of Saudi Arabia (KSA).
Representing the Company will be Co-Dx Chairman of the Board and CEO Dwight Egan, as well as the Company's President, Richard Abbott, Chief Commercialization and Strategy Officer Seth Egan, other department heads and critical staff, and Eugene Durenard from the Co-Diagnostics Board of Directors and Chairman of the Audit Committee.
The Exhibition brings together global leaders across public and private sectors, driving conversations around the future of healthcare innovation, investment and impact. This year, the Exhibition is expected to host over 160,000 healthcare professionals, and thousands of brands and investors representing countries across the Middle East and around the world.
On September 16, the Company announced a strategic Memorandum of Understanding (MOU) exploring a joint venture with a regional manufacturing and distribution company in the KSA. The joint venture would be anticipated to establish the development, manufacture, and sale of Co-Dx intellectual property throughout the Middle East and North Africa, including the Company's upcoming Co-Dx™ PCR point-of-care platform*. In addition to other Co-Dx infectious disease PCR products, Booth #H3.L17 will showcase this new platform to the sizable international audience of attendees.
*The Co-Dx PCR platform (including the Co-Dx PCR Home™, Co-Dx PCR Pro™, mobile app, and all associated tests and software) is subject to review by the FDA and/or other regulatory bodies and is not available for sale.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company's technologies are utilized for tests that are designed to detect and/or analyze nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory review and not currently for sale) and to identify genetic markers for use in applications other than infectious disease.
Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may include, but are not limited to, statements regarding the anticipated joint venture in the Kingdom of Saudi Arabia, potential licensing, development, manufacturing, distribution and commercialization of Co-Diagnostics' products, the availability of the Company's upcoming Co-Dx™ PCR platform, and the Company's ability to expand access to its diagnostic technologies in the Middle East and North Africa. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from those expressed or implied in these statements, including but not limited to risks described in the Company's filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. All forward-looking statements are based on current expectations and assumptions, and the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
Please note that we disclaim any responsibility for the content of external links provided in this press release. These links are provided solely for the reader's convenience and do not constitute endorsement by the Company.
SOURCE Co-Diagnostics
21 %
more press release views with